Jagsonpal Pharmaceuticals Allots 1,01,825 Equity Shares Under ESOP
Jagsonpal Pharmaceuticals allotted 1,01,825 equity shares under its ESOP 2022 plan on September 30, 2026. This increased the paid-up share capital to ₹13,21,18,490, comprising 6,60,59,245 equity shares. Shares were issued upon exercise of vested options.
The issuance of a relatively small number of shares under an employee stock option plan typically has a minimal impact on the overall share capital and market valuation of a company.
The allotment of shares under an ESOP plan is a routine corporate action and does not inherently indicate a positive or negative development for the company's financials or operations.
Jagsonpal Pharmaceuticals Limited has announced the allotment of 1,01,825 equity shares, each with a face value of ₹2, under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022 (JPL ESOP 2022). These shares were issued to eligible employees upon the exercise of vested options and will rank pari-passu with the existing equity shares of the company.
The allotment has resulted in an increase in the company's paid-up share capital. Prior to this allotment, the share capital stood at ₹13,19,14,840, comprising 6,59,57,420 equity shares. Post-allotment, the paid-up share capital has increased to ₹13,21,18,490, with the total number of equity shares now at 6,60,59,245.
The details provided under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, confirm the issuance of these shares on September 30, 2026. The exercise price varied for different tranches of shares, with 1,00,000 shares exercised at ₹94.00 each and 1,825 shares at ₹115.60 each. Correspondingly, the premium per share was ₹92.00 and ₹113.60, respectively.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.